A Phase 2 interventional study of Placebo and Intranasal esketamine (28 mg) in Depression, sponsored by Janssen Pharmaceutical K.K.. Completed at 46 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing esketamine in Depression — 11 open to participants now, 12 under way, 1 of them phase 3. Esketamine · Depression.
Among the 28 studies testing esketamine in Depression, this one is the 12th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 2nd registered.
8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.
Browse Depression studies →11 of the 28 studies testing esketamine in Depression are open now, in 3 countries. Recruiting first, the newest first:
Min Su · Sites in China
Ages 13–17
Yale University · Sites in United States
Ages 18+
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
China Medical University, China · Sites in China
Ages 18–65 · Women only
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 3 · Phase 4 7
First in 2012; this study’s year is marked. 1 started in 2016.
This study's enrollment of 202 is above the median of 81 across 7,078 interventional studies indexed under Depression.
Median enrollment 156 across the 28 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
19 studies in Depression by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 18 finished, 4 (22%) have results posted.
Among the 19 studies in Depression by Johnson & Johnson, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 2, and was the 16th registered.
Johnson & Johnson’s Depression studies by the year they started, since 2000.
4 of the studies testing esketamine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07179913The First Hospital of Jilin UniversityThe Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression | 2026-11-20 |
| NCT07247968Min SuSubanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | 2026-11-20 |
| NCT07367542Chinese PLA General HospitalEffect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery | 2027-02-01 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies testing esketamine in Depression, from their registry updates:
Among Johnson & Johnson’s 19 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
Drug: Placebo
Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
Drug: Intranasal esketamine (28 mg)
Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
Drug: Intranasal esketamine (56 mg)
Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
Drug: Intranasal esketamine (84 mg)
Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1) up to Day 28 (DB phase) induction
DB Induction Phase: Percentage of Participants With Response Based on MADRS Total Score
A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (\>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Days 2, 8, 15, 22 and 28 (DB induction phase)
DB Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score
A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Days 2, 8, 15, 22 and 28 (DB induction phase)
DB Induction Phase: Percentage of Participants Showing Onset of Clinical Response
A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Day 2 up to Day 28 (DB induction phase)
DB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.
Time frame: Baseline (Day 1) up to Day 28 (DB induction pahse)
DB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28
GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
Time frame: Baseline (Day 1) up to Day 28 (DB induction phase)
DB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28
SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.
Time frame: Baseline (Day 1) to Day 28 (DB induction phase)
Posttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12)
Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.
Time frame: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
Posttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission
Time to relapse in participants with response (\>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.
Time frame: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
Posttreatment Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Weeks 2, 4, 6, 8, 12, 16, 20 and 24
SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase
Time frame: Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)
OL Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score
A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Days 8, 15, 22 and 28 (OL induction phase)
OL Induction Phase: Change From Baseline (Prior to the First Dose of OL Induction Phase) in MADRS Total Score up to Endpoint OL Induction Phase (Last Post Baseline Assessment Value During the OL Induction Phase [OL: up to Day 28])
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])
OL Induction Phase: Percentage of Participants With Severity of Psychopathology on the CGI-S Scale
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time.
Time frame: Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])
| Milestone | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Esketamine: Flexible Dose |
|---|---|---|---|---|---|
| Started | 41 | 40 | 41 | 80 | 0 |
| Responders | 13 | 11 | 17 | 27 | 0 |
| Completed | 39 | 33 | 39 | 72 | 0 |
| Not completed | 2 | 7 | 2 | 8 | 0 |
| Withdrew: Adverse event | 1 | 4 | 2 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 1 | 0 |
| Milestone | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Esketamine: Flexible Dose |
|---|---|---|---|---|---|
| Started | 27 | 28 | 24 | 53 | 0 |
| Completed | 26 | 28 | 23 | 50 | 0 |
| Not completed | 1 | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 | 0 |
| Milestone | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Esketamine: Flexible Dose |
|---|---|---|---|---|---|
| Started | 13 | 11 | 17 | 27 | 0 |
| Completed | 12 | 8 | 16 | 25 | 0 |
| Not completed | 1 | 3 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 3 | 1 | 1 | 0 |
| Milestone | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Esketamine: Flexible Dose |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 48 |
| Completed | 0 | 0 | 0 | 0 | 47 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Milestone | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Esketamine: Flexible Dose |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 48 |
| Completed | 0 | 0 | 0 | 0 | 47 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
| Units on a scale | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 | -15.2 ± 13.07 | -14.5 ± 10.53 | -15.1 ± 12.21 | -15.3 ± 11.68 |
A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (\>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Day 2 | 22.0 | 13.2 | 10.0 | 9.0 |
| Day 8 | 2.4 | 2.6 | 9.8 | 3.8 |
| Day 15 | 17.5 | 8.3 | 15.0 | 18.2 |
| Day 22 | 23.1 | 13.9 | 20.5 | 29.7 |
| Day 28 | 33.3 | 35.3 | 43.6 | 37.5 |
A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Day 2 | 9.8 | 0 | 7.5 | 3.8 |
| Day 8 | 2.4 | 0 | 4.9 | 1.3 |
| Day 15 | 7.5 | 2.8 | 10.0 | 3.9 |
| Day 22 | 10.3 | 5.6 | 7.7 | 14.9 |
| Day 28 | 23.1 | 11.8 | 23.1 | 20.8 |
A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Onset of clinical response: Yes | 2.4 | 2.6 | 7.3 | 6.3 |
| Onset of clinical response: No | 97.6 | 97.4 | 92.7 | 93.7 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.
| Units on a scale | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| DB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28 | -1.0 (-5 to 1) | -1.0 (-3 to 0) | -1.0 (-5 to 0) | -1.0 (-4 to 1) |
GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
| Units on a scale | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| DB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28 | -8.2 ± 4.94 | -7.8 ± 5.05 | -8.1 ± 5.67 | -7.7 ± 5.05 |
SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.
| Units on a scale | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| DB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 | -8.6 ± 8.68 | -7.9 ± 7.94 | -9.5 ± 8.93 | -7.0 ± 7.39 |
Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.
| Days | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Posttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12) | 34.0 (26.0 to NA) | 52.0 (20.0 to 80.0) | 37.0 (19.0 to 71.0) | 30.0 (22.0 to 50.0) |
Time to relapse in participants with response (\>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.
| Days | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Posttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission | 32.0 (13.0 to 44.0) | 26.0 (9.0 to 121.0) | 79.5 (16.0 to 108.0) | 91.0 (22.0 to NA) |
SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase
| Units on a scale | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo |
|---|---|---|---|---|
| Week 2 | -14.6 ± 7.82 | -8.1 ± 6.15 | -13.1 ± 7.65 | -11.2 ± 6.83 |
| Week 4 | -12.9 ± 5.69 | -8.3 ± 2.75 | -13.6 ± 7.34 | -9.8 ± 5.84 |
| Week 6 | -17.7 ± 8.50 | -11.0 ± 3.61 | -14.6 ± 5.53 | -12.0 ± 4.39 |
| Week 8 | -12.0 ± 14.42 | -13.3 ± 1.53 | -15.3 ± 7.15 | -11.4 ± 6.02 |
| Week 12 | -20.5 ± 3.54 | -13.0 ± 7.21 | -18.3 ± 7.76 | -14.8 ± 4.88 |
| Week 16 | -21.5 ± 6.36 | -17.5 ± 0.71 | -12.5 ± 21.92 | -15.8 ± 1.89 |
| Week 20 | -22.0 ± 7.07 | -18.0 | -28.0 | -14.0 ± 3.65 |
| Week 24 | -21.5 ± 4.95 | -16.0 | -28.0 | -14.8 ± 3.59 |
A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Esketamine: Flexible Dose |
|---|---|
| Day 8 | 14.6 |
| Day 15 | 23.4 |
| Day 22 | 31.9 |
| Day 28 | 42.6 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Units on a scale | Esketamine: Flexible Dose |
|---|---|
| Baseline | 16.1 ± 9.47 |
| Change from baseline | -14.5 ± 11.06 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time.
| Percentage of participants | Esketamine: Flexible Dose |
|---|---|
| Normal, not at all ill:Baseline | 0 |
| Normal, not at all ill:Endpoint | 14.6 |
| Borderline mentally ill:Baseline | 0 |
| Borderline mentally ill:Endpoint | 16.7 |
| Mildly ill:Baseline | 4.2 |
| Mildly ill:Endpoint | 43.8 |
| Moderately ill:Baseline | 75.0 |
| Moderately ill:Endpoint | 20.8 |
| Markedly ill:Baseline | 14.6 |
| Markedly ill:Endpoint | 4.2 |
| Severely ill:Baseline | 4.2 |
| Severely ill:Endpoint | 0 |
| Among the most extremely ill patients:Baseline | 2.1 |
| Among the most extremely ill patients:Endpoint | 0 |
Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind (DB): Esketamine 28 mg | 0/41 (0%) | 1/41 (2.4%) | 33/41 (80.5%) |
| DB: Esketamine 56 mg | 0/41 (0%) | 0/41 (0%) | 39/41 (95.1%) |
| DB: Esketamine 84 mg | 0/40 (0%) | 1/40 (2.5%) | 39/40 (97.5%) |
| DB: Placebo | 0/80 (0%) | 1/80 (1.3%) | 34/80 (42.5%) |
| DB Follow Up (FU): Esketamine 28 mg | 0/27 (0%) | 0/27 (0%) | 3/27 (11.1%) |
| DB FU: Esketamine 56 mg | 0/29 (0%) | 0/29 (0%) | 3/29 (10.3%) |
| DB FU: Esketamine 84 mg | 0/23 (0%) | 1/23 (4.3%) | 3/23 (13%) |
| DB FU: Placebo | 0/53 (0%) | 2/53 (3.8%) | 7/53 (13.2%) |
| Post-Treatment (PT) Phase: Esketamine 28 mg | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| PT Phase: Esketamine 56 mg | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| PT Phase: Esketamine 84 mg | 0/17 (0%) | 0/17 (0%) | 6/17 (35.3%) |
| PT Phase: Placebo | 0/27 (0%) | 0/27 (0%) | 7/27 (25.9%) |
| Open-Label (OL): Flexible Esketamine | 0/48 (0%) | 1/48 (2.1%) | 47/48 (97.9%) |
| OL FU: Flexible Esketamine | 0/48 (0%) | 2/48 (4.2%) | 3/48 (6.3%) |
| Event | Double Blind (DB): Esketamine 28 mg | DB: Esketamine 56 mg | DB: Esketamine 84 mg | DB: Placebo | DB Follow Up (FU): Esketamine 28 mg | DB FU: Esketamine 56 mg | DB FU: Esketamine 84 mg | DB FU: Placebo | Post-Treatment (PT) Phase: Esketamine 28 mg | PT Phase: Esketamine 56 mg | PT Phase: Esketamine 84 mg | PT Phase: Placebo | Open-Label (OL): Flexible Esketamine | OL FU: Flexible Esketamine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 1/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 0/48 |
| Cerebral DisorderNervous system disorders | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 1/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 0/48 |
| Suicidal IdeationPsychiatric disorders | 0/41 | 0/41 | 1/40 | 1/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 0/48 |
| FractureInjury, poisoning and procedural complications | 1/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 0/48 |
| Atrioventricular Block Second DegreeCardiac disorders | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 1/48 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 1/48 |
| Suicide AttemptPsychiatric disorders | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 0/23 | 1/53 | 0/13 | 0/11 | 0/17 | 0/27 | 1/48 | 0/48 |
| Ankle FractureInjury, poisoning and procedural complications | 0/41 | 0/41 | 0/40 | 0/80 | 0/27 | 0/29 | 0/23 | 1/53 | 0/13 | 0/11 | 0/17 | 0/27 | 0/48 | 0/48 |
| Event | Double Blind (DB): Esketamine 28 mg | DB: Esketamine 56 mg | DB: Esketamine 84 mg | DB: Placebo | DB Follow Up (FU): Esketamine 28 mg | DB FU: Esketamine 56 mg | DB FU: Esketamine 84 mg | DB FU: Placebo | Post-Treatment (PT) Phase: Esketamine 28 mg | PT Phase: Esketamine 56 mg | PT Phase: Esketamine 84 mg | PT Phase: Placebo | Open-Label (OL): Flexible Esketamine | OL FU: Flexible Esketamine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DissociationPsychiatric disorders | 14/41 | 10/41 | 22/40 | 7/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 31/48 | 0/48 |
| Blood Pressure IncreasedInvestigations | 12/41 | 19/41 | 19/40 | 8/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 24/48 | 0/48 |
| DizzinessNervous system disorders | 11/41 | 18/41 | 15/40 | 5/80 | 1/27 | 1/29 | 0/23 | 1/53 | 1/13 | 0/11 | 0/17 | 0/27 | 21/48 | 0/48 |
| SomnolenceNervous system disorders | 10/41 | 13/41 | 11/40 | 14/80 | 0/27 | 0/29 | 0/23 | 1/53 | 1/13 | 0/11 | 0/17 | 0/27 | 11/48 | 0/48 |
| NauseaGastrointestinal disorders | 7/41 | 7/41 | 8/40 | 7/80 | 0/27 | 0/29 | 0/23 | 2/53 | 0/13 | 0/11 | 0/17 | 0/27 | 12/48 | 0/48 |
| VertigoEar and labyrinth disorders | 4/41 | 7/41 | 8/40 | 1/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 6/48 | 0/48 |
| HypoaesthesiaNervous system disorders | 7/41 | 8/41 | 5/40 | 4/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 0/17 | 0/27 | 6/48 | 1/48 |
| NasopharyngitisInfections and infestations | 1/41 | 0/41 | 1/40 | 3/80 | 2/27 | 1/29 | 1/23 | 3/53 | 2/13 | 2/11 | 2/17 | 3/27 | 2/48 | 2/48 |
| AstheniaGeneral disorders | 2/41 | 7/41 | 3/40 | 0/80 | 0/27 | 0/29 | 0/23 | 0/53 | 0/13 | 0/11 | 1/17 | 0/27 | 3/48 | 0/48 |
| HeadacheNervous system disorders | 6/41 | 5/41 | 4/40 | 3/80 | 0/27 | 0/29 | 1/23 | 0/53 | 0/13 | 0/11 | 1/17 | 2/27 | 8/48 | 0/48 |
Full analysis set (FAS) included all randomized participants who received at least 1 dose of intranasal study agent.
| Age, Continuous(years) | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 45.9 ± 9.97 | 42.5 ± 8.36 | 41.9 ± 10.26 | 43.3 ± 11.4 | 43.4 ± 10.35 |
| Sex: Female, Male(Participants) | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 23 | 16 | 18 | 39 | 96 |
| Male | 18 | 24 | 23 | 41 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 41 | 40 | 41 | 80 | 202 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 41 | 40 | 41 | 80 | 202 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Esketamine 28 Milligrams (mg) | Esketamine 56 mg | Esketamine 84 mg | Placebo | Total |
|---|---|---|---|---|---|
| JAPAN | 41 | 40 | 41 | 80 | 202 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Aug 2019, 32 months.
Results were first posted in Oct 2020, 1 year 2 months after primary completion.
Of 53 industry-sponsored phase 2 interventional studies under Depression, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 29. This study's 32 months is above that.
Counting every sponsor, half of 196 studies reached it within 31 months; a quarter within 18 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine